| abstract |
The invention relates to a heteroconjugate antibody which contains two binding functions. The first binding function is directed against an effector of peripheral blood effector cells, such as preferably the CD-3 antigen. The second function is directed against a specific domain of a protein covering the AIDS virus, such as preferably the V3 loop sequence of the envelope protein gp120, originating from HIV MN or a variant thereof. this. Also described are therapeutic methods, in which 20 ng / ml of a mixed culture of HIV-infected cells (effector cells and CEM-ss cells) produces an 80-90% decrease in reverse transcriptase activity compared to an identical culture having an effector cell / CEM-ss ratio equal to 3/1. |